Back to Annual Meeting

Back to Annual Meeting

APHA Scientific Session and Event Listing

Karolyn Motte, Master Science, Tobacco Use Prevention Service, Oklahoma State Department Health, 1000 N. E. 10th Street, oklahoma city, OK 73117, 405-271-3619, Karolynm@health.ok.gov and Deborah L. Thomas, RhD, Rehabilitation Counseling, Langston University, 4205 N. Lincoln Blvd., Oklahoma CIty, OK 73105.

Cigarette smoking among people with schizophrenia is a problem that can negatively affect both health and psychiatric treatment. Despite the focus on the health hazards of smoking, there are few reports of interventions for patients with schizophrenia and minimal studies that have reported on the use of population appropriate treatment approaches. Research indicates that 75% to 85% of people with schizophrenia in the United States smoke cigarettes compared with 23% in the general population. Several studies that address smoking cessation among persons with schizophrenia were analyzed for the present research. Various factors were noted as significant in contributing to the effectiveness of smoking cessation for this population. These factors included type of antipsychotic medication, inpatient or outpatient status, and behavioral treatment therapy. Results revealed that a combination of factors contributed to significant smoking cessation rates among persons with schizophrenia, to include combination behavioral treatment methods as opposed to using a single therapy, typical versus atypical antipsychotic medications, and the dosage of specific medications that were prescribed.

Learning Objectives:

• Increase awareness of effective smoking cessation programs based on therapeutic regimen
• Increase knowledge regarding reward systems that are counter-productive to smoking cessation in treatment program
• Enhance recognition of efficacy of smoking cessation programs utilized for individuals with schizophrenia

Keywords: Smoking Cessation, Mental Illness

Presenting author's disclosure statement:

Not Answered